1. In Vivo
  2. >>Business Strategy

Trends In Diagnostics 2011

In the 1967 movie classic The Graduate, Dustin Hoffman gets a one-word piece of career-planning advice from a family friend: “plastics.” In diagnostics, as it was last year, that word would have to be sequencing. But unlike last year, when the first item in our diagnostics trends piece cited the successful IPOs of next-generation sequencing companies Pacific Biosciences of California Inc. and Complete Genomics Inc., owing to the downturn in government funding and a slow economy, the tone in 2011 was more nuanced. [See Deal][See Deal] (SeeAlso see "Personalized Medicine In 2010: Welcome To The Establishment" - In Vivo, 1 January, 2011..) Share prices of sequencing market leaders Illumina Inc. and Life Technologies Corp. fell roughly 50% and 30%, respectively, in 2011. PacBio dropped more than 80% and Complete Genomics 60%, although the latter did manage to complete a secondary offering at $12.50 in June, more than 4x its current price.

More than a slowdown in instrument placements is affecting these instrument makers, however, and much of that spells good news...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.